MRNA Vaccines for COVID-19: What, Why and How

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2021 Apr 28

PMID 33907508

Citations 149

Authors

Jung Woo Park

Philip N P Lagniton

Yu Liu

Ren-He Xu

Affiliations

Soon will be listed here.

Abstract

The Coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2), has impacted human lives in the most profound ways with millions of infections and deaths. Scientists and pharmaceutical companies have been in race to produce vaccines against SARS-CoV-2. Vaccine generation usually demands years of developing and testing for efficacy and safety. However, it only took less than one year to generate two mRNA vaccines from their development to deployment. The rapid production time, cost-effectiveness, versatility in vaccine design, and clinically proven ability to induce cellular and humoral immune response have crowned mRNA vaccines with spotlights as most promising vaccine candidates in the fight against the pandemic. In this review, we discuss the general principles of mRNA vaccine design and working mechanisms of the vaccines, and provide an up-to-date summary of pre-clinical and clinical trials on seven anti-COVID-19 mRNA candidate vaccines, with the focus on the two mRNA vaccines already licensed for vaccination. In addition, we highlight the key strategies in designing mRNA vaccines to maximize the expression of immunogens and avoid intrinsic innate immune response. We also provide some perspective for future vaccine development against COVID-19 and other pathogens.

Citing Articles

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.

De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C Front Immunol. 2025; 16:1515748.

PMID: 39995659 PMC: 11847692. DOI: 10.3389/fimmu.2025.1515748.

Full sequencing of 100mer sgRNA via tandem mass spectrometry by targeted RNase H digestion with customized probes.

Gawlig C, Hirschberger R, Hanci G, Schott S, Marandi S, Hesse I Anal Bioanal Chem. 2025; 417(8):1497-1506.

PMID: 39833501 DOI: 10.1007/s00216-025-05737-y.

Design and Characterization of a Gene-Encoding DNA Nanoparticle in a Cell-Free Transcription-Translation System.

Galvan A, Green C, Hooe S, Oktay E, Thakur M, Diaz S ACS Appl Nano Mater. 2025; 7(11):12891-12902.

PMID: 39830902 PMC: 11741557. DOI: 10.1021/acsanm.4c01456.

mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases.

Brandi R, Paganelli A, DAmelio R, Giuliani P, Lista F, Salemi S Vaccines (Basel). 2025; 12(12.

PMID: 39772079 PMC: 11680146. DOI: 10.3390/vaccines12121418.

Nucleic acid functionalized extracellular vesicles as promising therapeutic systems for nanomedicine.

Liu C, He D, Cen H, Chen H, Li L, Nie G Extracell Vesicles Circ Nucl Acids. 2024; 3(1):14-30.

PMID: 39697871 PMC: 11648500. DOI: 10.20517/evcna.2021.21.

References

Cao J, Novoa E, Zhang Z, Chen W, Liu D, Choi G . High-throughput 5' UTR engineering for enhanced protein production in non-viral gene therapies. Nat Commun. 2021; 12(1):4138. PMC: 8260622. DOI: 10.1038/s41467-021-24436-7. View

Rigby R, Webb L, Mackenzie K, Li Y, Leitch A, Reijns M . RNA:DNA hybrids are a novel molecular pattern sensed by TLR9. EMBO J. 2014; 33(6):542-58. PMC: 3989650. DOI: 10.1002/embj.201386117. View

Quax T, Claassens N, Soll D, van der Oost J . Codon Bias as a Means to Fine-Tune Gene Expression. Mol Cell. 2015; 59(2):149-61. PMC: 4794256. DOI: 10.1016/j.molcel.2015.05.035. View

Folegatti P, Bittaye M, Flaxman A, Lopez F, Bellamy D, Kupke A . Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020; 20(7):816-826. PMC: 7172901. DOI: 10.1016/S1473-3099(20)30160-2. View

Radhakrishnan A, Chen Y, Martin S, Alhusaini N, Green R, Coller J . The DEAD-Box Protein Dhh1p Couples mRNA Decay and Translation by Monitoring Codon Optimality. Cell. 2016; 167(1):122-132.e9. PMC: 5635654. DOI: 10.1016/j.cell.2016.08.053. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Hoerr I, Obst R, Rammensee H, Jung G . In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 1999; 30(1):1-7. DOI: 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#. View

Zinder J, Lima C . Targeting RNA for processing or destruction by the eukaryotic RNA exosome and its cofactors. Genes Dev. 2017; 31(2):88-100. PMC: 5322736. DOI: 10.1101/gad.294769.116. View

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

10.

Roca-Ho H, Riera M, Palau V, Pascual J, Soler M . Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. Int J Mol Sci. 2017; 18(3). PMC: 5372579. DOI: 10.3390/ijms18030563. View

11.

Perri S, Greer C, Thudium K, Doe B, Legg H, Liu H . An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol. 2003; 77(19):10394-403. PMC: 228391. DOI: 10.1128/jvi.77.19.10394-10403.2003. View

12.

Callaway E . The coronavirus is mutating - does it matter?. Nature. 2020; 585(7824):174-177. DOI: 10.1038/d41586-020-02544-6. View

13.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

14.

Bloom K, van den Berg F, Arbuthnot P . Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2020; 28(3-4):117-129. PMC: 7580817. DOI: 10.1038/s41434-020-00204-y. View

15.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

16.

Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S . Memory B and memory plasma cells. Immunol Rev. 2010; 237(1):117-39. DOI: 10.1111/j.1600-065X.2010.00938.x. View

17.

de Alwis R, Gan E, Chen S, Leong Y, Tan H, Zhang S . A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Mol Ther. 2021; 29(6):1970-1983. PMC: 8019652. DOI: 10.1016/j.ymthe.2021.04.001. View

18.

Corbett K, Edwards D, Leist S, Abiona O, Boyoglu-Barnum S, Gillespie R . SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020; 586(7830):567-571. PMC: 7581537. DOI: 10.1038/s41586-020-2622-0. View

19.

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

20.

Sioud M . Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol. 2005; 348(5):1079-90. DOI: 10.1016/j.jmb.2005.03.013. View